Merck Reports Pimicotinib Tumor Response at Two Years in Phase 3 TGCT Study
Merck reported a tumor response at two years in its phase 3 study of pimicotinib for TGCT.
Merck reported a tumor response at two years in its phase 3 study of pimicotinib for TGCT.